%PDF-1.4
%
25 0 obj
<>
endobj
22 0 obj
<>
endobj
146 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T15:14:33Z
2024-03-28T16:26:05-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T16:26:05-07:00
application/pdf
Heather
2001-875.dec
uuid:f5fe754f-1dd1-11b2-0a00-2e0a275d6100
uuid:f5fe7551-1dd1-11b2-0a00-aa0000000000
endstream
endobj
11 0 obj
<>
endobj
12 0 obj
<>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
158 0 obj
[163 0 R]
endobj
159 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(risk of Hodgkin\222)55 (s and non-Hodgkin\222)55 (s lymphomas. Eur J Cancer)]TJ
0 Tc 0 -1.25 TD
(Prev 2000;9:59-64.)Tj
-2.175 -1.25 Td
[(24.)-875 (Hjelmstrom P)111 (. L)55 (ymphoid neogenesis: de novo formation of)]TJ
2.175 -1.25 Td
(lymphoid tissue in chronic inflammation through expression of)Tj
T*
(homing chemokines. J Leukoc Biol 2001;69:331-9.)Tj
-2.175 -1.25 Td
[(25.)-875 (Kamel OW)92 (, Holly EA, van de Rijn M, et al. )55 (A)-220 (population based,)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(case control study of non-Hodgkin\222)55 (s lymphoma in patients with)]TJ
0 Tc T*
(rheumatoid arthritis. J Rheumatol 1999;26:1676-80.)Tj
-2.175 -1.25 Td
[(26.)-875 (Stewart M, Malkovska )18 (V)129 (, Krishnan J, et al. L)55 (ymphoma in a patient)]TJ
2.175 -1.25 Td
(with rheumatoid arthritis receiving methotrexate treatment:)Tj
T*
[(successful treatment with rituximab. )55 (Ann Rheum Dis 2001;)]TJ
0 Tw T*
(60:892-3.)Tj
0.02499 Tw 30.825 13.75 Td
[(27.)-875 (Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody)]TJ
-0.00011 Tc 2.175 -1.25 Td
(\(rituximab\) for therapy of Epstein-Barr virus lymphoma after)Tj
0 Tc T*
(hemopoietic stem-cell transplantation. Blood 2000;95:1502-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875 (Swinnen L. Post-transplant lymphoproliferative disorders:)]TJ
0 Tc 2.175 -1.25 Td
(implications for acquired immunodeficiency syndrome-associated)Tj
T*
(malignancies. J Natl Cancer Inst Monogr 2001;28:38-43.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
(Starkebaum: Editorial)Tj
0 Tw 60.9375 -0.0313 Td
(2575)Tj
ET
0 0 0 0 scn
/GS0 gs
101.6 62.95 407.5 -10.84 re
f*
Q
Q
q
1 0 0 1 0 -4 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
101.6 62.95 407.5 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
66 0 obj
<>
endobj
152 0 obj
<>
endobj
29 0 obj
<>
endobj
31 0 obj
<>
endobj
28 0 obj
<>
endobj
53 0 obj
<>stream
HVpTι&B$$b%<,c<`$@&)
,JP
\(dLheF2@D(݄tg=s.vq/f|
(̣tlqr^QW\][M׀6rf(Wӑ
@4+/lxҧ_9 +t|C:2؏W :
6{^_Qw{;ӿr*5|W+לLRgVEYHQ@`!]!YA-`o%RB->,b@##X0$< XNۈC.fcqvb=b(/A5SMۿrb'ccq@['TUP7ƪCo5c*Gq?+rM`ZN;E"c縗]0K{5R [1O;rkN;D!8E"GpjC<1^T%F,o5G[|&@N
<.Oʯy]+I5>EjMi5Gӂ&iEZVd57BC{`GˑǓ63P2foYύcԱO,fv~=<@P@s]6I/.+Tf%#O->r8̓5
bbxImHqzװ.xZWyRcR0,V?7 Wp1t%3;=-Ϧ$w3~һvIJݩ3Gh&Lj1r
?'>Sh6O[zhYKO瑥c;]ٔc
h|sBlDŽjJiG墇+MӽחxC꿽Ɲ1CڑMdq-f5㍜NIK̼ޜ.W;p}Z{(6l'U
QK(1JS
L_ho!͌5r/=fZPifgsUF3\VX`epm-I^[⛥p<0ǚ'LLXڕi|gП5ޣ?q7-by+nI-{ۆ\